These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 22340363

  • 21. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z, Yang JK, Tong N, Yan S, Zhang X, Gong Y, Woerle HJ.
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [Abstract] [Full Text] [Related]

  • 23. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
    Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.
    Int J Clin Pract; 2013 Dec; 67(12):1283-93. PubMed ID: 24118640
    [Abstract] [Full Text] [Related]

  • 24. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.
    Lancet; 2013 Oct 26; 382(9902):1413-23. PubMed ID: 23948125
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 26; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 35. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.
    Diabetes Obes Metab; 2007 Mar 26; 9(2):166-74. PubMed ID: 17300592
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr 26; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 38. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators.
    Diabetes Obes Metab; 2009 Jun 26; 11(6):611-22. PubMed ID: 19515181
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.